Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Passes Below 50 Day Moving Average – Time to Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.28 and traded as low as $11.02. Bayer Aktiengesellschaft shares last traded at $11.05, with a volume of 972,243 shares trading hands.

Analyst Ratings Changes

BAYRY has been the subject of several recent analyst reports. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 9th. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 0.3%

The company’s 50 day moving average price is $11.28 and its 200 day moving average price is $11.04. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $43.43 billion, a price-to-earnings ratio of -17.27, a P/E/G ratio of 3.57 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The business had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, research analysts forecast that Bayer Aktiengesellschaft will post 1.24 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.